Weiss Ratings reissued a “sell (d-)” rating on shares of Passage Bio in a research report on Wednesday, June 24th. Get Passage Bio alerts:View Our Latest Analysis on PASGPassage Bio Price PerformancePASG opened at $4.52 on Thursday. Passage Bio has a one year low of $3.29 and a one year high of $20.00. Passage Bio Company Profile(Get Free Report)Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. Further ReadingReceive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.